Advice
Following a resubmission
Accepted for restricted use within NHS Scotland
Methyl aminolevulinate cream (Metvix) appears to be effective for the treatment of basal cell carcinoma in those patients in whom standard treatment with surgery or cryotherapy is contraindicated. Its use should be restricted to specialist dermatologists and to superficial lesions where penetration is most effective.
Download detailed advice20KB (PDF)
Medicine details
- Medicine name:
- Methyl aminolevulinate (Metvix cream®)
- SMC ID:
- 51/03
- Indication:
- Superficial and/or nodular basal cell carcinoma
- Pharmaceutical company
- Galderma (UK) Ltd
- BNF chapter
- Skin
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 10 November 2003